Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer

Oncotarget

Volumn 7, Issue 13, 2016, Pages 15460-15473

  Heo, Tae Hwe ^a,b   Wahler, Joseph ^b   Suh, Nanjoo ^b,c  

^a The Catholic University of Korea   (South Korea)

^b RUTGERS UNIVERSITY   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Breast cancer; Gp130; Interleukin 6

Indexed keywords

21 EPOXY RESIBUFOGENIN 3 ACETATE; 21 EPOXY RESIBUFOGENIN 3 FORMATE; ANTINEOPLASTIC AGENT; ELSILIMOMAB; GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LMT 28; MADINDOLINE A; MEDI 5117; MONOCLONAL ANTIBODY B P4; MONOCLONAL ANTIBODY B R3; PF 04236921; RALOXIFENE; SARILUMAB; SC 144; SILTUXIMAB; SIRUKUMAB; STAT3 PROTEIN; UNCLASSIFIED DRUG; IL6 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CHEMOTHERAPY; CYTOKINE PRODUCTION; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; HUMAN; NONHUMAN; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; FEMALE; METABOLISM; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CYTOKINE RECEPTOR GP130; FEMALE; HUMANS; INTERLEUKIN-6; RECEPTORS, INTERLEUKIN-6;

EID: 84967297558     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7102     Document Type: Article

References (103)

1. Ara T and DeClerck YA. Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer. 2010; 46:1223-1231.
2. Ataie-Kachoie P, Pourgholami MH and Morris DL. Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer. Cytokine Growth Factor Rev. 2013; 24:163-173.
3. Ataie-Kachoie P, Pourgholami MH, Richardson DR and Morris DL. Gene of the month: Interleukin 6 (IL-6). J Clin Pathol. 2014; 67:932-937.
4. Burger R. Impact of interleukin-6 in hematological malignancies. Transfus Med Hemother. 2013; 40:336-343.
5. Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, Thompson R, Schioppa T, Nemeth J, Vermeulen J, Singh N, Avril N, Cummings J, Rexhepaj E, Jirström K, Gallagher WM, et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res. 2011; 17:6083-6096.
6. Dethlefsen C, Højfeldt G and Hojman P. The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat. 2013; 138:657-664.
7. Guo Y, Xu F, Lu T, Duan Z and Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 2012; 38:904-910.
8. Jones SA, Scheller J and Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest. 2011; 121:3375-3383.
9. Nagasaki T, Hara M, Nakanishi H, Takahashi H, Sato M and Takeyama H. Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction. Br J Cancer. 2014; 110:469-478.
10. Rosean TR, Tompkins VS, Olivier AK, Sompallae R, Norian LA, Morse HC, Waldschmidt TJ and Janz S. The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in mice. Leukemia, 2015; 29:233-237.
11. Tanaka T and Kishimoto T. The biology and medical implications of interleukin-6. Cancer Immunol Res. 2014; 2:288-294.
12. Taniguchi K and Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol. 2014; 26:54-74.
13. Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M and Yao Y. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther. 2014; 141:125-139.
14. Di G-H, Liu Y, Lu Y, Liu J, Wu C and Duan H-F. IL-6 secreted from senescent mesenchymal stem cells promotes proliferation and migration of breast cancer cells. PLoS ONE. 2014; 9:e113572.
15. Nagasaki T, Hara M, Shiga K and Takeyama H. Relationship between inflammation and cancer progression: Recent advances in interleukin-6 signaling and its blockage in cancer therapy. Receptors Clin Investig. 2014; 1:e202.
16. Kishimoto T. The biology of interleukin-6. Blood. 1989; 74:1-10.
17. Santhanam U, Ghrayeb J, Sehgal PB and May LT. Post-translational modifications of human interleukin-6. Arch Biochem Biophys. 1989; 274:161-170.
18. Boulanger MJ, Chow D-c, Brevnova EE and Garcia KC. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science. 2003; 300:2101-2104.
19. Rose-John S. The biology of interleukin-6 in the 21st century. Semin Immunol. 2014; 26:1.
20. Allocca M, Jovani M, Fiorino G, Schreiber S and Danese S. Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target. Curr Drug Targets. 2013; 14:1508-1521.
21. Scheller J, Garbers C and Rose-John S. Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities. Semin Immunol. 2014; 26:2-12.
22. Xu S and Neamati N. gp130: a promising drug target for cancer therapy. Expert Opin Ther Targets. 2013; 17:1303-1328.
23. Calabrese LH and Rose-John S. IL-6 biology: implications for clinical targeting in rheumatic disease. Nat Rev Rheumatol. 2014; 10:720-727.
24. Garcia-Tuñón I, Ricote M, Ruiz A, Fraile B, Paniagua R and Royuela M. IL-6, its receptors and its relationship with bcl-2 and bax proteins in infiltrating and in situ human breast carcinoma. Histopathology. 2005; 47:82-89.
25. Benoy I, Salgado R, Colpaert C, Weytjens R, Vermeulen PB and Dirix LY. Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer. 2002; 2:311-315.
26. Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissière F, Laune D, Roques S and Lazennec G. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res. 2007; 9:R15.
27. Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, Huget P and Dirix LY. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer. 2003; 103:642-646.
28. Zhang GJ and Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res. 1999; 19:1427-1432.
29. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, et al. Molecular portraits of human breast tumours. Nature. 2000; 406:747-752.
30. Allred DC, Brown P and Medina D. The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res. 2004; 6:240-245.
31. Shah N, Jin K, Cruz L-A, Park S, Sadik H, Cho S, Goswami CP, Nakshatri H, Gupta R, Chang HY, Zhang Z, Cimino-Mathews A, Cope L, Umbricht C and Sukumar S. HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression. Cancer Res. 2013; 73:5449-5458.
32. Won HS, Kim Y-A, Lee JS, Jeon EK, An HJ, Sun DS, Ko YH and Kim JS. Soluble interleukin-6 receptor is a prognostic marker for relapse-free survival in estrogen receptor-positive breast cancer. Cancer Invest. 2013; 31:516-521.
33. Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, Ceccarelli C, Santini D, Paterini P, Marcu KB, Chieco P and Bonafè M. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest. 2007; 117:3988-4002.
34. Sun X, Mao Y, Wang J, Zu L, Hao M, Cheng G, Qu Q, Cui D, Keller ET, Chen X, Shen K and Wang J. IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer. Oncogene. 2014:1-10.
35. Pauletti G, Godolphin W, Press MF and Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996; 13:63-72.
36. Hartman ZC, Yang X-Y, Glass O, Lei G, Osada T, Dave SS, Morse MA, Clay TM and Lyerly HK. HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis. Cancer Res. 2011; 71:4380-4391.
37. Conze D, Weiss L, Regen PS, Bhushan A, Weaver D, Johnson P and Rincón M. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res. 2001; 61:8851-8858.
38. Korkaya H, Kim G-I, Davis A, Malik F, Henry NL, Ithimakin S, Quraishi AA, Tawakkol N, D'Angelo R, Paulson AK, Chung S, Luther T, Paholak HJ, Liu S, Hassan KA, Zen Q, et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell. 2012; 47:570-584.
39. Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol. 2012; 23:vi7-vi12.
40. Hartman ZC, Poage GM, den Hollander P, Tsimelzon A, Hill J, Panupinthu N, Zhang Y, Mazumdar A, Hilsenbeck SG, Mills GB and Brown PH. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res. 2013; 73:3470-3480.
41. Alshaker H, Wang Q, Frampton AE, Krell J, Waxman J, Winkler M, Stebbing J, Cooper C, Yagüe E and Pchejetski D. Sphingosine kinase 1 contributes to leptin-induced STAT3 phosphorylation through IL-6/gp130 transactivation in oestrogen receptor-negative breast cancer. Breast Cancer Res Treat. 2015; 149:59-67.
42. Pietras K and Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res. 2010; 316:1324-1331.
43. Korkaya H, Liu S and Wicha MS. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest. 2011; 121:3804-3809.
44. Erez N, Glanz S, Raz Y, Avivi C and Barshack I. Cancer associated fibroblasts express pro-inflammatory factors in human breast and ovarian tumors. Biochem Biophys Res Commun. 2013; 437:397-402.
45. Studebaker AW, Storci G, Werbeck JL, Sansone P, Sasser AK, Tavolari S, Huang T, Chan MWY, Marini FC, Rosol TJ, Bonafè M and Hall BM. Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. Cancer Res. 2008; 68:9087-9095.
46. Lieblein JC, Ball S, Hutzen B, Sasser AK, Lin H-J, Huang TH, Hall BM and Lin J. STAT3 can be activated through paracrine signaling in breast epithelial cells. BMC Cancer. 2008; 8:302-315.
47. Mullard A. Green light for Janssen's IL-6 blocker. Nat Biotechnol. 2014; 32:607.
48. Dorff TB, Goldman B, Pinski JK, Mack PC, Lara PN, Van Veldhuizen PJ, Quinn DI, Vogelzang NJ, Thompson IM and Hussain MHA. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res. 2010; 16:3028-3034.
49. Guo Y, Nemeth J, O'Brien C, Susa M, Liu X, Zhang Z, Choy E, Mankin H, Hornicek F and Duan Z. Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer. Clin Cancer Res. 2010; 16:5759-5769.
50. Hudes G, Tagawa ST, Whang YE, Qi M, Qin X, Puchalski TA, Reddy M, Cornfeld M and Eisenberger M. A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer. Invest New Drugs. 2012; 31:669-676.
51. Hunsucker SA, Magarotto V, Kuhn DJ, Kornblau SM, Wang M, Weber DM, Thomas SK, Shah JJ, Voorhees PM, Xie H, Cornfeld M, Nemeth JA and Orlowski RZ. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol. 2011; 152:579-592.
52. Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani SZ, van de Velde H, Qin X, Puchalski TA, Hall B, Reddy M, Qi M, et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res. 2013; 19:3659-3670.
53. Markham A and Patel T. Siltuximab: First Global Approval. Drugs. 2014; 74:1147-1152.
54. Rossi J-F, Négrier S, James ND, Kocak I, Hawkins R, Davis H, Prabhakar U, Qin X, Mulders P and Berns B. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer. 2010; 103:1154-1162.
55. Song L, Smith MA, Doshi P, Sasser K, Fulp W, Altiok S and Haura EB. Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer. J Thorac Oncol. 2014; 9:974-982.
56. Voorhees PM, Manges RF, Sonneveld P, Jagannath S, Somlo G, Krishnan A, Lentzsch S, Frank RC, Zweegman S, Wijermans PW, Orlowski RZ, Kranenburg B, Hall B, Casneuf T, Qin X, van de Velde H, et al. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol. 2013; 161:357-366.
57. Cavarretta IT, Neuwirt H, Zaki MH, Steiner H, Hobisch A, Nemeth JA and Culig Z. Mcl-1 is regulated by IL-6 and mediates the survival activity of the cytokine in a model of late stage prostate carcinoma. Adv Exp Med Biol. 2008; 617:547-555.
58. Chari A, Pri-Chen H and Jagannath S. Complete remission achieved with single agent CNTO 328, an anti-IL-6 monoclonal antibody, in relapsed and refractory myeloma. Clin Lymphoma Myeloma Leuk. 2013; 13:333-337.
59. Orlowski RZ, Gercheva L, Williams C, Sutherland H, Robak T, Masszi T, Goranova-Marinova V, Dimopoulos MA, Cavenagh JD, Spička I, Maiolino A, Suvorov A, Bladé J, Samoylova O, Puchalski TA, Reddy M, et al. A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. Am J Hematol. 2015; 90:42-49.
60. Rossi JF, Lu ZY, Jourdan M and Klein B. Interleukin-6 as a therapeutic target. Clin Cancer Res. 2015; 21:1248-1257.
61. Xu Z, Bouman-Thio E, Comisar C, Frederick B, Van Hartingsveldt B, Marini JC, Davis HM and Zhou H. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol. 2011; 72:270-281.
62. Smolen JS, Weinblatt ME, Sheng S, Zhuang Y and Hsu B. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2014; 73:1616-1625.
63. Shaw S, Bourne T, Meier C, Carrington B, Gelinas R, Henry A, Popplewell A, Adams R, Baker T, Rapecki S, Marshall D, Moore A, Neale H and Lawson A. Discovery and characterization of olokizumab: A humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. MAbs. 2014; 6:774-782.
64. Kretsos K, Golor G, Jullion A and Hickling M. Safety and pharmacokinetics of olokizumab, an antiIL6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study. Clin Pharmacol Drug Devel. 2014; 3:388-395.
65. Klein B, Wijdenes J, Zhang XG, Jourdan M, Boiron JM, Brochier J, Liautard J, Merlin M, Clement C and Morel-Fournier B. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood. 1991; 78:1198-1204.
66. Fulciniti M, Hideshima T, Vermot-Desroches C, Pozzi S, Nanjappa P, Shen Z, Patel N, Smith ES, Wang W, Prabhala R, Tai Y-T, Tassone P, Anderson KC and Munshi NC. A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res. 2009; 15:7144-7152.
67. Mease P, Strand V, Shalamberidze L, Dimic A, Raskina T, Xu L-A, Liu Y and Smith J. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann Rheum Dis. 2012; 71:1183-1189.
68. Bayliss TJ, Smith JT, Schuster M, Dragnev KH and Rigas JR. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther. 2011; 11:1663-1668.
69. Silverman J, Lu Q, Bakker A, To W, Duguay A, Alba BM, Smith R, Rivas A, Li P, Le H, Whitehorn E, Moore KW, Swimmer C, Perlroth V, Vogt M, Kolkman J, et al. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat Biotechnol. 2005; 23:1556-1561.
70. Zinzalla G, Haque MR, Basu BP, Anderson J, Kaye SL, Haider S, Hasan F, Antonow D, Essex S, Rahman KM, Palmer J, Morgenstern D, Wilderspin AF, Neidle S and Thurston DE. A novel small-molecule inhibitor of IL-6 signalling. Bioorg Med Chem Lett. 2010; 20:7029-7032.
71. Jostock T, Mullberg J, Ozbek S, Atreya R, Blinn G, Voltz N, Fischer M, Neurath MF and Rose-John S. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem. 2001; 268:160-167.
72. Matsumoto S, Hara T, Mitsuyama K, Yamamoto M, Tsuruta O, Sata M, Scheller J, Rose-John S, Kado S-i and Takada T. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J Immunol. 2010; 184:1543-1551.
73. Tanaka Y and Martin Mola E. IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab. Ann Rheum Dis. 2014; 73:1595-1597.
74. Ando K, Takahashi F, Motojima S, Nakashima K, Kaneko N, Hoshi K and Takahashi K. Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia. J Clin Oncol. 2013; 31:e69-72.
75. Narita Y, Kitamura H, Wakita D, Sumida K, Masuko K, Terada S, Nakano K and Nishimura T. The key role of IL-6-arginase cascade for inducing dendritic cell-dependent CD4(+) T cell dysfunction in tumor-bearing mice. J Immunol. 2013; 190:812-820.
76. Sumida K, Wakita D, Narita Y, Masuko K, Terada S, Watanabe K, Satoh T, Kitamura H and Nishimura T. Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses. Eur J Immunol. 2012; 42:2060-2072.
77. Oguro T, Ishibashi K, Sugino T, Hashimoto K, Tomita S, Takahashi N, Yanagida T, Haga N, Aikawa K, Suzutani T, Yamaguchi O and Kojima Y. Humanised antihuman IL-6R antibody with interferon inhibits renal cell carcinoma cell growth in vitro and in vivo through suppressed SOCS3 expression. Eur J Cancer. 2013; 49:1715-1724.
78. Zhang L, Luan B, Adler A, Eichten A, Daly C and Thurston G. Abstract 2723: Sarilumab (REGN88), a fully-human anti-IL6R antibody, inhibits tumor growth in preclinical models, as a single agent and in combination with the VEGF blocker aflibercept. Cancer Res. 2012; 72:2723-2723.
79. Mintz CS and Crea R. Protein scaffolds the next generation of protein therapeutics? Bioprocess Int. 2013; 11:40-48.
80. Yoshio-Hoshino N, Adachi Y, Aoki C, Pereboev A, Curiel DT and Nishimoto N. Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor. Cancer Res. 2007; 67:871-875.
81. Savino R, Ciapponi L, Lahm A, Demartis A, Cabibbo A, Toniatti C, Delmastro P, Altamura S and Ciliberto G. Rational design of a receptor super-antagonist of human interleukin-6. EMBO J. 1994; 13:5863-5870.
82. Demartis A, Bernassola F, Savino R, Melino G and Ciliberto G. Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death. Cancer Res. 1996; 56:4213-4218.
83. Sporeno E, Savino R, Ciapponi L, Paonessa G, Cabibbo A, Lahm A, Pulkki K, Sun RX, Toniatti C, Klein B and Ciliberto G. Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells. Blood. 1996; 87:4510-4519.
84. Hönemann D, Chatterjee M, Savino R, Bommert K, Burger R, Gramatzki M, Dörken B and Bargou RC. The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells. Int J Cancer. 2001; 93:674-680.
85. Tassone P, Neri P, Burger R, Savino R, Shammas M, Catley L, Podar K, Chauhan D, Masciari S, Gozzini A, Tagliaferri P, Venuta S, Munshi NC and Anderson KC. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Clin Cancer Res. 2005; 11:4251-4258.
86. Hayashi M, Rho M-C, Fukami A, Enomoto A, Nonaka S, Sekiguchi Y, Yanagisawa T, Yamashita A, Nogawa T, Kamano Y and Komiyama K. Biological activity of a novel nonpeptide antagonist to the interleukin-6 receptor 20S,21-epoxy-resibufogenin-3-formate. J Pharmacol Exp Ther. 2002; 303:104-109.
87. Enomoto A, Rho M-C, Fukami A, Hiraku O, Komiyama K and Hayashi M. Suppression of cancer cachexia by 20S,21-epoxy-resibufogenin-3-acetate-a novel nonpeptide IL-6 receptor antagonist. Biochem Biophys Res Commun. 2004; 323:1096-1102.
88. Hong SS, Choi JH, Lee SY, Park YH, Park KY, Lee JY, Kim J, Gajulapati V, Goo JI, Singh S, Lee K, Kim YK, Im SH, Ahn SH, Rose-John S, Heo TH, et al. A Novel Small-Molecule Inhibitor Targeting the IL-6 Receptor Subunit, Glycoprotein 130. J Immunol. 2015; 195:237-245.
89. Chevalier S, Fourcin M, Robledo O, Wijdenes J, Pouplard-Barthelaix A and Gascan H. Interleukin-6 family of cytokines induced activation of different functional sites expressed by gp130 transducing protein. J Biol Chem. 1996; 271:14764-14772.
90. Sommer J, Effenberger T, Volpi E, Waetzig GH, Bernhardt M, Suthaus J, Garbers C, Rose-John S, Floss DM and Scheller J. Constitutively active mutant gp130 receptor protein from inflammatory hepatocellular adenoma is inhibited by an anti-gp130 antibody that specifically neutralizes interleukin 11 signaling. J Biol Chem. 2012; 287:13743-13751.
91. Hayashi M, Rho M-C, Enomoto A, Fukami A, Kim Y-P, Kikuchi Y, Sunazuka T, Hirose T, Komiyama K and Omura S. Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130. Proc Natl Acad Sci USA. 2002; 99:14728-14733.
92. Saleh AZM, Greenman KL, Billings S, Van Vranken DL and Krolewski JJ. Binding of madindoline A to the extracellular domain of gp130. Biochemistry. 2005; 44:10822-10827.
93. Yamamoto D, Sunazuka T, Hirose T, Kojima N, Kaji E and Omura S. Design, synthesis, and biological activities of madindoline analogues. Bioorg Med Chem Lett. 2006; 16:2807-2811.
94. Xu S, Grande F, Garofalo A and Neamati N. Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer. Mol Cancer Ther. 2013; 12:937-949.
95. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK and Investigators RUfTHRT. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006; 355:125-137.
96. Miller PD, Chines AA, Christiansen C, Hoeck HC, Kendler DL, Lewiecki EM, Woodson G, Levine AB, Constantine G and Delmas PD. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women:2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res. 2008; 23:525-535.
97. Li H, Xiao H, Lin L, Jou D, Kumari V, Lin J and Li C. Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface. J Med Chem. 2014; 57:632-641.
98. Kim S-J, Chin Y-W and Heo T-H. Erythropoietic agents from natural sources. Altern Ther Health Med. 2013; 19:54-60.
99. San-Miguel J, Bladé J, Shpilberg O, Grosicki S, Maloisel F, Min C-K, Polo Zarzuela M, Robak T, Prasad SVSS, Tee Goh Y, Laubach J, Spencer A, Mateos M-V, Palumbo A, Puchalski T, Reddy M, et al. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood. 2014; 123:4136-4142.
100. Pinski JK, Goldman B, Dorff T, Mack P, Lara PJ, van Veldhuizen P, Quinn D, Hussain MH and Thompson IM. SWOG S0354: A phase II trial of CNTO328, a monoclonal antibody against interleukin-6 (IL-6), in chemotherapy pretreated patients (pts) with castration-resistant prostate cancer (CRPC). ASCO Meeting Abstracts. 2009; 27:5143.
101. Ando K, Takahashi F, Kato M, Kaneko N, Doi T, Ohe Y, Koizumi F, Nishio K and Takahashi K. Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer. PLoS ONE. 2014; 9:e102436.
102. Hirata H, Tetsumoto S, Kijima T, Kida H, Kumagai T, Takahashi R, Otani Y, Inoue K, Kuhara H, Shimada K, Nagatomo I, Takeda Y, Goya S, Yoshizaki K, Kawase I, Tachibana I, et al. Favorable responses to tocilizumab in two patients with cancer-related cachexia. J Pain Symptom Manage. 2013; 46:e9-e13.
103. Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A, Burg J, Strand S, Kiesslich R, Huber S, Ito H, Nishimoto N, Yoshizaki K, Kishimoto T, Galle PR, Blessing M, et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity. 2004; 21:491-501.